“The FDA was changing leucovorin's label because it could help 'hundreds of thousands' of children with autism”
Summary
FDA Commissioner Marty Makary announced in September 2025 that the agency would change leucovorin's label to reflect potential benefits for some children with autism and cerebral folate deficiency. However, the FDA later clarified the label change applied to a rare subset of patients with a specific metabolic condition, not hundreds of thousands of children, and the agency disputed characterizations that overstated the scope of the change.
Primary Sources
Reports that FDA distanced itself from claims about leucovorin helping hundreds of thousands of autism patients after initial announcements by Commissioner Makary
Announced FDA would update leucovorin label to reflect use in children with autism and cerebral folate deficiency
Made claims about leucovorin potentially helping hundreds of thousands of children with autism
Evidence Supporting the Claim
- FDA Commissioner Marty Makary announced in September 2025 that the FDA would change leucovorin's label to reflect its use in children with autism and cerebral folate deficiency
- The FDA did proceed with a label change for leucovorin related to autism treatment in some capacity
- Leucovorin has been studied for use in children with autism spectrum disorder who have cerebral folate deficiency
Evidence Against / Context
- The FDA clarified the label change applied to a rare subset of patients with cerebral folate deficiency, not hundreds of thousands of children with autism broadly
- Cerebral folate deficiency is a rare metabolic condition affecting a small number of children with autism, not the general autism population
- The FDA backed away from characterizations that suggested the drug would help hundreds of thousands of children, indicating this figure significantly overstated the scope
- The claim conflates a label change for a specific rare condition with a broader treatment application for autism generally
Timeline
FDA Commissioner Marty Makary announced the agency would update leucovorin's label for use in children with autism and cerebral folate deficiency
HHS Secretary RFK Jr. made statements suggesting leucovorin could help hundreds of thousands of children with autism
FDA clarified the label change applied to a rare subset of patients and distanced itself from broader claims about helping hundreds of thousands of children
What This Means
Structured interpretation — not opinion
Key takeaway 1
The FDA did initiate a label change for leucovorin related to autism treatment, but the scope was limited to children with a specific rare condition called cerebral folate deficiency
Key takeaway 2
Cerebral folate deficiency affects a small subset of children with autism spectrum disorder, not the broader autism population of hundreds of thousands suggested in some characterizations
Key takeaway 3
The claim accurately reflects that a label change occurred but significantly overstates the number of children who might benefit from the treatment
Key takeaway 4
Label changes by the FDA reflect updates to approved uses or indications based on available evidence, but do not necessarily indicate widespread applicability
Related Claims in health
“The Trump administration enacted a 6-month moratorium on Minnesota Medicaid payments”
On February 27, 2026, the Trump administration implemented a six-month moratorium on federal Medicaid payments to Minnesota through the Centers for Medicare and Medicaid Services. The action was taken in response to Minnesota's policies regarding undocumented immigrants' access to state healthcare programs, which federal officials characterized as violations of federal law.
“90% of health care spending treats chronic disease”
The claim that 90% of healthcare spending treats chronic disease is an overstatement of the actual figures. Federal health agencies report that chronic diseases account for approximately 75-90% of healthcare spending, with the most commonly cited figure from the Centers for Disease Control and Prevention being 90% of the nation's $4.5 trillion in annual healthcare expenditures, though this appears to include broadly defined chronic conditions and may represent an upper-bound estimate.
“Americans are now paying the lowest price anywhere in the world for drugs, thanks to the administration's negotiations with pharmaceutical companies”
The claim that Americans pay the lowest drug prices in the world is contradicted by international data. While the Trump administration negotiated some drug pricing agreements, U.S. prescription drug prices remain substantially higher than those in other developed countries.